Vitreous penetration of topical moxifloxacin and gatifloxacin in humans

Retina. 2006 Feb;26(2):191-5. doi: 10.1097/00006982-200602000-00012.

Abstract

Purpose: To determine the vitreous penetration of the new fourth-generation topical fluoroquinolones moxifloxacin 0.5% and gatifloxacin 0.3%.

Methods: A prospective randomized clinical trial comprising 12 eyes of 12 patients scheduled for pars plana vitrectomy between August 2003 and September 2003 was performed in a clinical practice. The patients were randomly assigned to receive topical moxifloxacin 0.5% (n = 6) or gatifloxacin 0.3% (n = 6). One half the patients in each antibiotic group received 1 drop every 15 minutes for a total of 3 doses starting 1 hour before surgery, and the other one half self-administered the antibiotic drop 4 times daily for 3 days before surgery and at 7 am on the day of surgery. Undiluted vitreous samples were obtained and analyzed using high-performance liquid chromatography.

Results: Either moxifloxacin 0.5% or gatifloxacin 0.3% was detected in the vitreous in all 12 patients in the study. There was no significant difference between the mean vitreous concentration of moxifloxacin 0.5% given over 1 hour preoperatively (0.012 +/- 0.011 microg/mL) and that given in the 3-day regimen (0.011 +/- 0.008 microg/mL) (P = 0.93). There was also no significant difference between the mean vitreous concentration of gatifloxacin 0.3% given over 1 hour preoperatively (0.001 +/- 0.0003 microg/mL) and that given over 3 days (0.008 +/- 0.006 microg/mL) (P = 0.11). Vitreous concentrations of moxifloxacin 0.5% and gatifloxacin 0.3% in each eye were all lower than the 90% minimum inhibitory concentration for the commonest bacterial isolates causing endophthalmitis. With both dosing regimens, the mean vitreous concentration of moxifloxacin 0.5% was higher than that of gatifloxacin 0.3% administered at the same regimen, but this was not statistically significant.

Conclusion: Both topical moxifloxacin 0.5% and gatifloxacin 0.3% penetrated the vitreous in the uninflamed eye, but the vitreous concentrations attained were all lower than the 90% minimum inhibitory concentration for the commonest bacterial pathogens causing acute postoperative endophthalmitis.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Topical
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / pharmacokinetics*
  • Aza Compounds / administration & dosage
  • Aza Compounds / pharmacokinetics*
  • Biological Availability
  • Chromatography, High Pressure Liquid
  • Fluoroquinolones / administration & dosage
  • Fluoroquinolones / pharmacokinetics*
  • Gatifloxacin
  • Humans
  • Lens, Crystalline / physiology
  • Microbial Sensitivity Tests
  • Middle Aged
  • Moxifloxacin
  • Ophthalmic Solutions / administration & dosage
  • Ophthalmic Solutions / pharmacokinetics
  • Prospective Studies
  • Pseudophakia / metabolism
  • Quinolines / administration & dosage
  • Quinolines / pharmacokinetics*
  • Retinal Diseases / surgery
  • Vitrectomy
  • Vitreous Body / metabolism*
  • Vitreous Hemorrhage / surgery

Substances

  • Anti-Bacterial Agents
  • Aza Compounds
  • Fluoroquinolones
  • Ophthalmic Solutions
  • Quinolines
  • Gatifloxacin
  • Moxifloxacin